Bone Transport Accelerates Diabetic Foot Ulcer Healing via TGF-β1–Mediated Angiogenic and Osteo-Immune Coupling

Study Background and Research Question

Diabetic foot ulcers (DFUs) represent a severe complication of diabetes mellitus, affecting 15–25% of diabetic patients and often leading to chronic wounds, infections, or even amputation. Traditional therapies—including conservative wound care and surgical debridement—have limited success in treating extensive or recalcitrant ulcers, especially those complicated by peripheral artery disease and ischemia. Recent advances in reconstructive surgery have explored bone transport (BT), or distraction osteogenesis, as a method to promote both osteogenesis and angiogenesis. However, the molecular mechanisms underlying BT’s therapeutic effects, particularly the role of the transforming growth factor-beta 1 (TGF-β1) signaling pathway, have remained insufficiently characterized.

Key Innovation from the Reference Study

The reference study, published in Journal of Molecular Histology (2026), provides the first systematic in vivo demonstration that BT accelerates DFU healing through activation of the TGF-β1/TGFBR1 signaling axis. Uniquely, the research links TGF-β1 signaling not only to angiogenesis but also to the coupling of bone regeneration with immune modulation at the wound site. This dual mechanism—termed "angiogenic and osteo-immune coupling"—highlights a previously underappreciated synergy between skeletal tissue repair and vascular-immune crosstalk in chronic wound environments.

Methods and Experimental Design Insights

The investigators utilized a robust rat model of ischemic DFU, assigning seventy-five Sprague-Dawley rats into three groups: sham (osteotomy without distraction), BT, and BT with TGF-β1 pathway inhibition (BTI). The BTI group received a selective TGF-β1 pathway inhibitor to delineate the pathway’s specific contribution. Wound healing progression was assessed through serial digital measurements and histological analysis. To probe molecular mechanisms, the study integrated proteomics, ELISA, RT-qPCR, and immunohistochemistry, enabling a comprehensive evaluation of both local and systemic changes in TGF-β1 signaling and downstream effectors.

• Proteomic profiling identified differentially expressed proteins in wound tissue.
• ELISA quantified serum concentrations of TGF-β1 and vascular endothelial growth factor (VEGF).
• RT-qPCR and immunohistochemistry assessed expression of TGF-β1, its receptor TGFBR1, VEGF, and α-smooth muscle actin (α-SMA).

Core Findings and Why They Matter

The BT group exhibited markedly accelerated wound closure, increased dermal thickness, and enhanced re-epithelialization compared to both sham and BTI groups. These effects correlated with upregulation of TGF-β1 and TGFBR1 expression, as well as heightened activation of the TGF-β1/TGFBR1 signaling pathway at wound sites. Systemically, BT stimulated complement activation and immune regulation, suggesting involvement of both innate and adaptive immunity. Importantly, serum and tissue levels of TGF-β1 and VEGF were significantly elevated after BT, underlining the pathway’s role in promoting angiogenesis and wound vascularization.

In the BTI group, inhibition of the TGF-β1 pathway led to attenuated healing responses, blunted angiogenesis, and reduced osteo-immune modulation. This provides direct evidence that the pathway is not merely associated with, but functionally required for, the enhanced wound healing seen with bone transport.

These findings establish TGF-β1 as a central mediator coupling bone-derived signals to both vascular regeneration and immune adaptation during chronic wound healing. The results suggest that targeted manipulation of the TGF-β1/TGFBR1 axis could provide a rational therapeutic strategy for otherwise recalcitrant diabetic wounds.

Comparison with Existing Internal Articles

The results of this reference study are consistent with and extend the conclusions of prior internal reviews. For example, "Bone Transport Accelerates Diabetic Foot Ulcer Healing via TGF-β1 Pathway" and "Bone Transport Enhances Diabetic Foot Ulcer Repair via TGF-β1 Pathway" both highlight BT-induced activation of TGF-β1 signaling as a driver of angiogenesis and immune modulation. The present study provides a more detailed mechanistic framework, adding proteomics and in vivo functional inhibition data to clarify causality and the breadth of osteo-immune-vascular coupling. This complements earlier pathway-focused summaries and strengthens the rationale for targeting TGF-β1 in chronic wound research.

Moreover, internal resources such as "SB525334: A Selective TGF-beta1 Receptor Inhibitor for Fibrosis Models" and "SB525334: Precision TGF-beta1 Receptor Inhibition in Fibrosis Models" discuss the use of selective inhibitors like SB525334 to interrogate TGF-β signaling in preclinical models, further supporting the translational relevance of pathway-targeted strategies in both fibrosis and wound healing contexts.

Limitations and Transferability

While this study offers compelling evidence of TGF-β1–mediated coupling in rat models of DFU, several limitations should be noted. First, the use of rodent models may not fully capture the complexity of human wound healing, particularly regarding immune cell heterogeneity and chronicity of disease. Second, the specific TGF-β1 pathway inhibitor used was not named in detail, though similar compounds such as SB525334 are known to provide selective ALK5 (TGF-β1 receptor) inhibition. The study did not directly address potential off-target effects or long-term safety of pathway inhibition in vivo.

Transferability of findings to clinical scenarios will require further validation in large animal models and, ultimately, human trials. Nonetheless, the demonstration that TGF-β1/TGFBR1 signaling orchestrates both angiogenic and immune responses positions this pathway as a high-priority target for translational wound healing research.

Protocol Parameters

• Animal model: Ischemic diabetic foot ulcer in Sprague-Dawley rats; random assignment to sham, BT, and BT + TGF-β1 pathway inhibition groups.
• Bone transport procedure: Osteotomy followed by gradual distraction; wound healing monitored over serial intervals.
• TGF-β1 pathway inhibition: Selective inhibitor administered in the BTI group; use when dissecting TGF-β1 pathway contributions in vivo.
• Assessment methods: Histology, serial wound measurement, proteomics, ELISA for TGF-β1/VEGF, RT-qPCR, immunohistochemistry for molecular pathway markers.

Research Support Resources

Researchers aiming to model or modulate the TGF-β1 signaling pathway in chronic wound or fibrosis contexts can employ well-characterized, selective inhibitors such as SB525334 (TGF-beta1 receptor inhibitor) (SKU A5602). This compound enables targeted inhibition of ALK5, effectively blocking TGF-β1-induced Smad2/3 phosphorylation and downstream signaling, as detailed in product documentation. SB525334 is widely used for dissecting TGF-β1 pathway function in both cellular and animal models of fibrosis and tissue repair, and can support workflows comparable to those described in this study. For detailed handling and storage guidelines, researchers should consult the product information. APExBIO provides additional resources for experimental design and troubleshooting in TGF-β pathway research.